Bionano Genomics (BNGO) stock surged 7.64% in the pre-market session on Monday.
The rally comes after the company announced positive results from a study at Johns Hopkins University School of Medicine, showing that its Optical Genome Mapping (OGM) technology outperformed multiple cytogenetic assays in the analysis of bone and soft tissue tumors. Key findings included: - OGM detected 100% of variants found by standard techniques like karyotyping and FISH - OGM was more sensitive, detecting diagnostic variants missed by karyotyping in 74% of failed/negative cases - Combined with next-generation sequencing, OGM found diagnostic variants in ~98% of cases, substantially higher than standard methods The researchers highlighted OGM's potential to qualify more patients for targeted therapies or clinical trials based on the additional variants detected.
The positive study results suggest increasing adoption potential for Bionano's OGM technology beyond blood cancers into solid tumor analysis as well.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.